Position in EXEL
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$217,204
+$51,735 QoQ
Shares Held
3,992
+3.5% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#575
of 751 holders
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 95%
Shared 0%
None 5%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Johnson Financial Group, Inc. holds $2,424,373 across 21 Biotechnology names. EXEL ranks #2 (9.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,250 | $2,026,504 | |
| 2 | EXEL |
Exelixis, Inc.
This page
|
3,992 | $217,204 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
134 | $66,561 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
200 | $37,456 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
142 | $34,217 | |
| 6 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
143 | $11,655 | |
| 7 | ABVX |
Abivax S.A.
|
62 | $8,262 | |
| 8 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
49 | $4,776 |
All Filings in EXEL
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $217,204 | 3,992 | Shares | Defined | 2026-08-10 | |
| 2026-03-31 | $165,469 | 3,858 | Shares | Defined | 2026-05-07 | |
| 2025-12-31 | $169,096 | 3,858 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $153,140 | 3,708 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $177,465 | 4,026 | Shares | Defined | 2025-08-13 | |
| 2025-03-31 | $7,384 | 200 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $6,660 | 200 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $5,190 | 200 | Shares | Defined | 2024-11-13 | |
| 2024-03-31 | $4,746 | 200 | Shares | Defined | 2024-05-14 | |
| No filing history on record for this holder in this stock. | ||||||